BACKGROUND: The purpose of this study was to analyze response to palliative low-dose involved-field radiotherapy (LD-IF-RT) (two 2-Gy fractions), explore factors predicting for response, and determine the time course to subsequent treatment. PATIENTS AND METHODS: Thirty-three patients with advanced or recurrent indolent non-Hodgkin's lymphoma (NHL) received LD-IF-RT to 43 sites. Response was assessed by physical examination and radiographic studies. Median follow-up for individual sites was 14 months. Fisher's exact test was used to evaluate prognostic factors for response and in-field progression. RESULTS: Overall response was 95%. Thirty-six sites (84%) had a complete response (CR), five sites (12%) had a partial response, and two sites (5%) had progressive disease. The CR rate of head and neck sites was significantly higher than that of pelvic and/or inguinofemoral sites (95% versus 64%, P = 0.04). The CR rate was significantly higher for sites < or =40 mm than for sites >40 mm (90% versus 56%, P = 0.04). Ten sites (23%) had in-field progression diagnosed at a median of 9 months. Sixteen patients (48%) received systemic treatment at a median of 8 months. Fourteen patients (42%) did not require additional treatment. CONCLUSIONS: LD-IF-RT for selected NHL subtypes has excellent local CR and in-field control rates and may postpone the need for systemic therapy.
BACKGROUND: The purpose of this study was to analyze response to palliative low-dose involved-field radiotherapy (LD-IF-RT) (two 2-Gy fractions), explore factors predicting for response, and determine the time course to subsequent treatment. PATIENTS AND METHODS: Thirty-three patients with advanced or recurrent indolent non-Hodgkin's lymphoma (NHL) received LD-IF-RT to 43 sites. Response was assessed by physical examination and radiographic studies. Median follow-up for individual sites was 14 months. Fisher's exact test was used to evaluate prognostic factors for response and in-field progression. RESULTS: Overall response was 95%. Thirty-six sites (84%) had a complete response (CR), five sites (12%) had a partial response, and two sites (5%) had progressive disease. The CR rate of head and neck sites was significantly higher than that of pelvic and/or inguinofemoral sites (95% versus 64%, P = 0.04). The CR rate was significantly higher for sites < or =40 mm than for sites >40 mm (90% versus 56%, P = 0.04). Ten sites (23%) had in-field progression diagnosed at a median of 9 months. Sixteen patients (48%) received systemic treatment at a median of 8 months. Fourteen patients (42%) did not require additional treatment. CONCLUSIONS:LD-IF-RT for selected NHL subtypes has excellent local CR and in-field control rates and may postpone the need for systemic therapy.
Authors: Beverly A Guadagnolo; Sigui Li; Donna Neuberg; Andrea Ng; Ling Hua; Barbara Silver; Mary Ann Stevenson; Peter Mauch Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-21 Impact factor: 7.038
Authors: T Girinsky; D Guillot-Vals; S Koscielny; J M Cosset; G Ganem; P Carde; M Monhonval; R Pereira; J Bosq; V Ribrag; J M Vantelon; J N Munck Journal: Int J Radiat Oncol Biol Phys Date: 2001-09-01 Impact factor: 7.038
Authors: R L M Haas; Ph Poortmans; D de Jong; M Verheij; M van der Hulst; J P de Boer; H Bartelink Journal: Eur J Cancer Date: 2005-08 Impact factor: 9.162
Authors: G Ganem; P Lambin; G Socié; T Girinsky; J Bosq; J L Pico; P Solal-Céligny; J M Cosset Journal: Hematol Oncol Date: 1994 Jan-Feb Impact factor: 5.271
Authors: Silvia Montoto; Andrew John Davies; Janet Matthews; Maria Calaminici; Andrew J Norton; John Amess; Sarah Vinnicombe; Rachel Waters; Ama Z S Rohatiner; T Andrew Lister Journal: J Clin Oncol Date: 2007-05-07 Impact factor: 44.544
Authors: Carolina E Fasola; Jennifer C Jones; Derek D Huang; Quynh-Thu Le; Richard T Hoppe; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-29 Impact factor: 7.038
Authors: Daniel Rolf; Gabriele Reinartz; Stephan Rehn; Christopher Kittel; Hans Theodor Eich Journal: Cancers (Basel) Date: 2022-02-10 Impact factor: 6.639
Authors: Brandon S Imber; Karen W Chau; Jasme Lee; Jisun Lee; Dana L Casey; Joanna C Yang; N Ari Wijentunga; Annemarie Shepherd; Carla Hajj; Shunan Qi; Monica R Chelius; Paul A Hamlin; M Lia Palomba; Erel Joffe; Zhigang Zhang; Andrew D Zelenetz; Gilles A Salles; Joachim Yahalom Journal: Blood Adv Date: 2021-10-26